Trial Profile

A Phase I Clinical Trial of an Infusion of Autologous T Cells Genetically Engineered With a Chimeric Receptor to Target the Follicle-Stimulating Hormone Receptor in Patients With Recurrent Ovarian Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ovarian cancer chimeric endocrine receptor T-cell therapy-Anixa Biosciences (Primary) ; Ovarian cancer chimeric endocrine receptor T-cell therapy-Anixa Biosciences (Primary)
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions; First in man
Sponsors Anixa Biosciences

23 Jun 2025 According to an Anixa Biosciences media release, the first patient in the fourth dosage cohort in the ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer has been dosed
09 Jun 2025 According to an Anixa Biosciences media release, company will present data from this study in an e-poster at the European Society for Medical Oncology ("ESMO") Gynaecological Cancers Congress 2025, to be held on June 19-21, 2025 in Vienna, Austria.
21 May 2025 Planned number of patients changed from 48 to 10.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com